恶性纤维组织细胞瘤(MFH)是最常见的软组织肉瘤,常发生于四肢软组织,其治疗趋势为以手术为主的综合治疗.肿瘤分期、病理类型及治疗方式均与其预后相关.近年来涌现了大量有关MFH治疗及预后的分子生物学方面的研究,为MFH的治疗及预后评价提供了新的前景.%Malignant fibrous histiocytoma( MFH )is the most common subtype of soft-tissue sarcoma that mainly occurs in the soft tissues of the extremities. Surgical resection has generally been accepted as the treatment of first choice for MFH. Tumor stage, metastases and operationmodes are the correlated factors of prognosis. In recent years, many shudies focused on therapy and prognosis for MFH in molecular biology are emerging,promised a novel prospect for targeting therapy and prognostic evaluation for MFH.
展开▼
